Flow Cytometry reported by customer review using biotinylated antibody
Immunocytochemistry/Immunofluorescence reported in scientific literature (PMID 24885572)
Immunohistochemistry reported in scientific literature (PMID 24174657)
Immunohistochemistry-Frozen reported in scientific literature (PMID 24885572)
Immunohistochemistry-Paraffin reported in scientific literature (PMID 25004090)
Western Blot 0.5 ug/ml
In Western blot, a band is seen ~31 kDa. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
31 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
PBS and 30% Glycerol
0.1% Sodium Azide
Immunogen affinity purified
Alternate Names for DIO3 Antibody - BSA Free
deiodinase, iodothyronine, type III
thyroxine deiodinase type III (selenoprotein)
Type 3 DI
type 3 iodothyronine selenodeiodinase
type III iodothyronine deiodinase
type-III 5' deiodinase
DIO3 (type III iodothyronine deiodinase), an iodothyronine deiodinase family member, is expressed in placenta and several fetal tissues in the plasma/endosomal membranes as single-pass type II membrane protein, and it catalyzes the deiodination of T4 (3,5,3',5'-tetraiodothyronine) into RT3 (3,3',5'-triiodothyronine) and of T3 (3,5,3'-triiodothyronine) into T2 (3,3'-diiodothyronine), both RT3 and T2 being inactive metabolites thus preventing premature exposure of developing fetus to adult levels of thyroid hormones. DIO3 controls circulating thyroid hormone levels throughout gestation by controlling thyroid hormone inactivation during embryological development. DIO3 is homodimeric and may undergo minor heretodimerization with DIO1 or DIO2, homo- or heterodimer state being critical for its catalytic activity. Its activity has been identified in only a limited number of postnatal tissues, i.e. brain, skin, and pregnant uterus, whereas it is abundantly present in several fetal tissues. Furthermore, DIO3 re-expression has been shown in certain pathologies that include cancer, cardiac hypertrophy, myocardial infarction, chronic inflammation, and critical illness.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
FAQs for DIO3 Antibody (NBP1-05767). (Showing 1 - 2 of 2 FAQs).
I am looking for a Dio3 peptide that I can inject in vivo to produce a biological effect. Can you provide information or confirm whether the Dio3 peptide you have would be effective as a biological agent in vivo?
I have pulled up information on the Dio3 peptides and recombinant proteins that we have available. Unfortunately I would not expect any of them to be biologically active and capable of producing a response when injected in vivo. The two peptides we carry are simply intended to be used for negative control competition assays to block signal of the primary and determine what is specific and non-specific as far as signal is concerned. The other two recombinant proteins are ones we distribute for a Taiwanese company called Abnova and they should not be biologically active based on the cell free wheat germ system employed to synthesize them. We will typically list our active proteins with an indication of such on our datasheet if it has been tested and usually the application of functional listed.
We have used one of your antibodies against Dio3 (cat# NBP1-05767) in the past and, despite it being directed against rodent D3 peptide sequence, it also appears to stains human D3 specifically in our hands. Can you please let us know the rodent D3 peptide sequence that was used to create this antibody? Alternatively, can you let us know if this rodent D3 peptide sequence also matches the human D3 peptide sequence? If there is a high degree of sequence homology, we wish to publish our findings and include a description that your antibody works in human tissues (IHC).We also noticed a new D3 aB on your website (cat# NBP1-19747) that is said to recognize human D3. Can you also let me know the sequence of the peptide used to generate it? We are one of the only labs in the world that study D3. If you can send us some samples of these antibodies, we can likely help you validate them experimentally for Western, IHC, etc.
The immunogen shares 93% homology to human. It is expected to cross-react with human cells. Furthermore, full-length DIO3 in human and mouse share greater than 95% similarity over the entire protein. It will be very difficult to find an antibody that works on one species but not the other unless the immunogen falls within amino acids 48-55, which is the only region where there is significant difference between the two species. It is highly doubtful you will find a commercial antibody that uses this immunogen to generate their antibody as most companies will want to increase the amount of species recognized by an antibody, not decrease it. For NBP1-19747, like all of our immunogens, the exact sequence is considered proprietary, but as you can see on our datasheet, the immunogen surrounds amino acid 66, which does not fall within the range where mouse and human are dissimilar.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.